Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Hold" by Brokerages

Key Points

• Analysts assign Rezolute an average recommendation of Hold from 11 covering brokers (1 sell, 4 hold, 6 buy), with an average 1‑year price target of $8.00.
• Rezolute is a clinical‑stage biopharma whose lead candidate, RZ358, is in Phase 2b for congenital hyperinsulinism, and it is also developing RZ402 for diabetic macular edema.
• Shares trade near $3.59 with a market cap of $343.6M; the company reported a quarterly EPS loss of ($0.22) (missing estimates) and is forecast to post about -0.93 EPS for the fiscal year, while institutional investors own roughly 82.97% of the stock.

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) has been assigned an average recommendation of "Hold" from the eleven analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $8.00.

RZLT has been the subject of a number of recent analyst reports. Wedbush raised Rezolute from a "neutral" rating to an "outperform" rating and lifted their price objective for the company from $2.00 to $5.00 in a research report on Wednesday, March 25th. BTIG Research reiterated a "buy" rating and issued a $5.00 target price on shares of Rezolute in a report on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rezolute in a research note on Thursday, January 22nd.

Institutional Trading of Rezolute

A number of institutional investors have recently modified their holdings of RZLT. BNP Paribas Financial Markets purchased a new stake in shares of Rezolute during the 2nd quarter worth about $25,000. ExodusPoint Capital Management LP purchased a new stake in shares of Rezolute during the 4th quarter worth about $25,000. HB Wealth Management LLC purchased a new stake in shares of Rezolute during the 4th quarter worth about $26,000. Fifth Third Wealth Advisors LLC purchased a new stake in shares of Rezolute during the 4th quarter worth about $29,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Rezolute during the 4th quarter worth about $29,000. Hedge funds and other institutional investors own 82.97% of the company's stock.

Rezolute Stock Up 1.1%

Shares of NASDAQ:RZLT opened at $3.59 on Thursday. The company has a market cap of $343.56 million, a P/E ratio of -3.86 and a beta of 0.65. Rezolute has a 52 week low of $1.07 and a 52 week high of $11.46. The business has a fifty day simple moving average of $3.18 and a 200-day simple moving average of $5.33.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.06). Sell-side analysts expect that Rezolute will post -0.93 earnings per share for the current fiscal year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.